“Cerebral Adrenoleukodystrophy (CALD) Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Cerebral Adrenoleukodystrophy Market.
The Cerebral Adrenoleukodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report provides detailed insights about emerging therapies for the treatment of Cerebral Adrenoleukodystrophy and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cerebral Adrenoleukodystrophy Treatment.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Cerebral Adrenoleukodystrophy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
DelveInsight’s Report covers around 3+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Key Clinical and Commercial Developments in the Cerebral Adrenoleukodystrophy (CALD) Therapeutics Market
• On September 16, 2022, bluebird bio, Inc. (Nasdaq: BLUE) announced that the US FDA had granted accelerated approval for its gene therapy SKYSONA® (elivaldogene autotemcel), also known as eli-cel. SKYSONA® has generated positive results and slowed the progression of neurologic dysfunction in boys 4-17 years of age with early, active Cerebral Adrenoleukodystrophy (CALD).
Learn How the Ongoing Clinical & Commercial Activities will Affect the Cerebral Adrenoleukodystrophy Therapeutic Segment:
Cerebral Adrenoleukodystrophy (CALD) Therapeutics Landscape
There are approx. 3+ key companies which are developing therapies for Cerebral Adrenoleukodystrophy. Currently, Minoryx Therapeutics has its Cerebral Adrenoleukodystrophy drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Cerebral Adrenoleukodystrophy (CALD) Therapeutic Market include:
• Minoryx Therapeutics
• POXEL SA
• Orpheris, Inc.
• bluebird bio, Inc.
• Minoryx Therapeutics
• Magenta Therapeutics
And many others
Cerebral Adrenoleukodystrophy (CALD) Emerging Drugs Covered in the report include:
• MIN-102: Minoryx Therapeutics
• PXL770: POXEL SA
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Cerebral Adrenoleukodystrophy Current Treatment Patterns
4. Cerebral Adrenoleukodystrophy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Cerebral Adrenoleukodystrophy Late Stage Products (Phase-III)
7. Cerebral Adrenoleukodystrophy Mid-Stage Products (Phase-II)
8. Cerebral Adrenoleukodystrophy Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cerebral Adrenoleukodystrophy Discontinued Products
13. Cerebral Adrenoleukodystrophy Product Profiles
14. Key Companies in the Cerebral Adrenoleukodystrophy Market
15. Key Products in the Cerebral Adrenoleukodystrophy Therapeutics Segment
16. Dormant and Discontinued Products
17. Cerebral Adrenoleukodystrophy Unmet Needs
18. Cerebral Adrenoleukodystrophy Future Perspectives
19. Cerebral Adrenoleukodystrophy Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Metastatic HER2 Positive Breast Cancer Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Metastatic HER2 Positive Breast Cancer Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States